Instil Bio Inc (TIL) FinancialsTILFinancialInstil Bio Inc

Evaluating the bottom line, Instil Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -25.33%, provide a clear picture of how effectively TIL converts its operational activities into shareholder value.

In the context of the broader market, TIL competes directly with industry leaders such as ZYBT and TCRX. With a market capitalization of $50.05M, it holds a significant position in the sector. When comparing efficiency, TIL's gross margin of N/A stands against ZYBT's 20.51% and TCRX's 100.00%. Such benchmarking helps identify whether Instil Bio, Inc. is trading at a premium or discount relative to its financial performance.

Instil Bio has shown a net loss improvement, with Q2 2026 loss per share at -$0.63, down from -$3.24 in Q2 2025. However, the company continues to operate at a loss, with a total cash position declining from $76.3 million to $69.9 million over the last few quarters, indicating financial strain.